{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:19:04Z","timestamp":1788254344510,"version":"build-2803163510"},"reference-count":34,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>The Japanese label specifies suvorexant 20 mg once nightly for adults and 15 mg once nightly for older adults, but dose selection has not been characterized across all doses. We conducted a single-center retrospective drug-utilization study of outpatient prescriptions and inpatient medication orders at a Japanese university hospital during 2023\u20132025. Dose and prescription-date age were reconstructed, and patient-cluster bootstrap confidence intervals addressed repeated prescriptions. Among 3755 records, 15 mg accounted for 68.4%, 20 mg for 29.9%, and 10 mg and other calculable doses each for 0.9%. Of 3685 age-classifiable 15\/20 mg records, 2529 were concordant with the operational age-based framework (68.6%; 95% CI 62.5\u201374.2). Non-concordance predominantly comprised 15 mg in patients younger than 65 years (841\/1646; 51.1%); 20 mg in patients aged 65 years or older occurred in 315\/2039 records (15.4%). Concordance was 65.0% in outpatient and 73.8% in inpatient records. Full-dose retention revealed uncommon 7.5- and 30-mg selections that a binary analysis would omit. Together, these findings provide a descriptive, single-center, full-dose, age- and setting-stratified basis for medication-use evaluation and targeted contextual review.<\/jats:p>","DOI":"10.3390\/pharmacy14060127","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:31:13Z","timestamp":1788251473000},"page":"127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Full-Dose Distribution and Age\u2013Dose Concordance of Suvorexant: A Retrospective Drug Utilization Study at a Japanese University Hospital"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-5130","authenticated-orcid":false,"given":"Shinya","family":"Kajiura","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Palliative Medicine, Toyama University Hospital, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6818-8673","authenticated-orcid":false,"given":"Nobukazu","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Toyama University Hospital, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Shingo","family":"Chikaoka","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Toyama University Hospital, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Yuta","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Toyama University Hospital, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Naohiko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Palliative Medicine, Toyama University Hospital, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8022-196X","authenticated-orcid":false,"given":"Atsushi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Toyama University Hospital, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4205-9540","authenticated-orcid":false,"given":"Ryuji","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Palliative Medicine, Toyama University Hospital, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7326\/M15-2175","article-title":"Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians","volume":"165","author":"Qaseem","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J. Clin. Sleep Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0140-6736(22)00878-9","article-title":"Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: A systematic review and network meta-analysis","volume":"400","author":"Ostinelli","year":"2022","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"(2023). American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc., 71, 2052\u20132081.","DOI":"10.1111\/jgs.18372"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102312","DOI":"10.1016\/j.japh.2024.102312","article-title":"Exploring the pharmacist role in insomnia management and care provision: A scoping review","volume":"65","author":"Basheti","year":"2025","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1021\/jm100541c","article-title":"Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia","volume":"53","author":"Cox","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/2042098615595359","article-title":"Suvorexant in insomnia: Efficacy, safety and place in therapy","volume":"6","author":"Rhyne","year":"2015","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40261-018-0650-4","article-title":"Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men","volume":"38","author":"Yee","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41398-025-03439-8","article-title":"Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: A systematic review and network meta-analysis","volume":"15","author":"Kishi","year":"2025","journal-title":"Transl. Psychiatry"},{"key":"ref_10","unstructured":"Pharmaceuticals and Medical Devices Agency (2026, August 04). Belsomra Tablets 10 mg\/15 mg\/20 mg [Japanese Electronic Package Insert]. Available online: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/170050_1190023F1024_1_19."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.5664\/jcsm.6116","article-title":"Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials","volume":"12","author":"Herring","year":"2016","journal-title":"J. Clin. Sleep Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jagp.2017.03.004","article-title":"Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials","volume":"25","author":"Herring","year":"2017","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40261-019-00764-x","article-title":"Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects","volume":"39","author":"Wrishko","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"ref_14","unstructured":"U.S. Food and Drug Administration (2026, August 02). BELSOMRA (Suvorexant) Tablets, Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/204569s010lbl.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.282.15.1458","article-title":"Why don\u2019t physicians follow clinical practice guidelines? A framework for improvement","volume":"282","author":"Cabana","year":"1999","journal-title":"JAMA"},{"key":"ref_16","unstructured":"World Health Organization (2003). Introduction to Drug Utilization Research, World Health Organization."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ajhp\/zxaa393","article-title":"ASHP Guidelines on Medication-Use Evaluation","volume":"78","author":"Afanasjeva","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","article-title":"Outcomes for implementation research: Conceptual distinctions, measurement challenges, and research agenda","volume":"38","author":"Proctor","year":"2011","journal-title":"Adm. Policy Ment. Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/acps.13661","article-title":"Sleep medicines are often prescribed for older adults (\u226575 years) without appropriate dosing instructions: A nationwide retrospective register study in Finland","volume":"149","author":"Eronen","year":"2024","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: A phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"212517","DOI":"10.7573\/dic.212517","article-title":"Suvorexant for insomnia in older adults: A perspective review","volume":"7","author":"Tampi","year":"2018","journal-title":"Drugs Context"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"zsx178","DOI":"10.1093\/sleep\/zsx178","article-title":"Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts","volume":"41","author":"Svetnik","year":"2018","journal-title":"Sleep"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.5665\/sleep.5168","article-title":"On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers","volume":"38","author":"Vermeeren","year":"2015","journal-title":"Sleep"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00213-016-4375-x","article-title":"On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly","volume":"233","author":"Vermeeren","year":"2016","journal-title":"Psychopharmacology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/jgs.13701","article-title":"How to Use the American Geriatrics Society 2015 Beers Criteria-A Guide for Patients, Clinicians, Health Systems, and Payors","volume":"63","author":"Steinman","year":"2015","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40268-018-0256-6","article-title":"Suvorexant (Belsomra(\u00ae) Tablets 10, 15, and 20 mg): Japanese Drug-Use Results Survey","volume":"19","author":"Asai","year":"2019","journal-title":"Drugs R D."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/03007995.2019.1700361","article-title":"Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: A sub-analysis of the post-marketing drug-use results survey in Japan","volume":"36","author":"Takeuchi","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.9758\/cpn.2018.16.2.184","article-title":"Assessment of Switching to Suvorexant versus the Use of Add-on Suvorexant in Combination with Benzodiazepine Receptor Agonists in Insomnia Patients: A Retrospective Study","volume":"16","author":"Hatano","year":"2018","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.5664\/jcsm.10946","article-title":"A retrospective clinical practice study comparing the usefulness of dual-orexin receptor antagonists and a melatonin receptor agonist in patients switching from long-term benzodiazepine receptor agonists","volume":"20","author":"Tachibana","year":"2024","journal-title":"J. Clin. Sleep Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40801-023-00356-4","article-title":"Factors Associated with Prescriptions for an Orexin Receptor Antagonist Among Japanese Patients with Insomnia: Analysis of a Nationwide Japanese Claims Database","volume":"10","author":"Okuda","year":"2023","journal-title":"Drugs\u2014Real World Outcomes"},{"key":"ref_32","first-page":"Cd000259","article-title":"Audit and feedback: Effects on professional practice","volume":"6","author":"Ivers","year":"2026","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/M15-2248","article-title":"Practice Feedback Interventions: 15 Suggestions for Optimizing Effectiveness","volume":"164","author":"Brehaut","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.7326\/M13-3001","article-title":"Using default options within the electronic health record to increase the prescribing of generic-equivalent medications: A quasi-experimental study","volume":"161","author":"Patel","year":"2014","journal-title":"Ann. Intern. Med."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/14\/6\/127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:53:25Z","timestamp":1788252805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/14\/6\/127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmacy14060127"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy14060127","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}